Literature DB >> 15538829

In-vitro activity of 5-fluorocytosine against 1,021 Spanish clinical isolates of Candida and other medically important yeasts.

Guillermo Quindós1, María Teresa Ruesga, Estrella Martín-Mazuelos, Ricardo Salesa, Rocío Alonso-Vargas, Alfonso Javier Carrillo-Muñoz, Sonia Brena, Rosario San Millán, José Pontón.   

Abstract

The aim of this study was to determine the prevalence of primary resistance to 5-fluorocytosine (5FC) among clinical isolates of yeasts in Spain where this drug is not currently available for therapy. We have tested the in vitro activity of 5FC against 1,021 recent yeast clinical isolates, including 522 Candida albicans, 140 Candida parapsilosis, 68 Candida glabrata, 41 Candida dubliniensis, 50 Candida guilliermondii, 34 Candida tropicalis, 28 Candida krusei, 20 Candida famata, 11 Cryptococcus neoformans, 5 Cryptococcus albidus, 43 Rhodotorula spp., 24 Trichosporon spp., 5 Saccharomyces cerevisiae, 9 Pichia spp., and 21 isolates from other 11 yeast species. The MICs were determined by the ATB Fungus agar microdilution test (bioMerieux, France) and the following interpretive breakpoints were used: susceptible, > 4 microg/ml; intermediate, 8 to 16 microg/ml; resistant, > 32 microg/ml. 5FC was very active against Candida spp. and other medically important yeasts as 852 (83.4%) of the studied isolates were susceptible (MIC < 4 microg/ml). The species most susceptible to 5FC were C. dubliniensis (100%of isolates; MIC90, 0.25 microg/ml), C. famata (100% of isolates; MIC90, 0.25 microg/ml), C. guilliermondii (98%of isolates; MIC90, 0.25 microg/ml), C. glabrata (95.5% of isolates; MIC90, 0.25 microg/ml), and C. neoformans (90.9% of isolates; MIC90, 2 microg/ml). Primary resistance to 5FC was very uncommon, and a MIC > 32 microg/ml, indicator of in vitro resistance, was observed in 106 isolates (10.4%): 77 C. albicans (16.5% of isolates; MIC90, > 128 microg/ml), 9 C. parapsilosis (6.4% of isolates; MIC90, 8 microg/ml), 4 C. albidus (80% of isolates, MIC50, > 128 microg/ml), 3 C. glabrata (4.4% of isolates; MIC90, 0.25 microg/ml), 3 C. tropicalis (8.8% of isolates; MIC90, 4 microg/ml), 2 C. krusei (7.1% of isolates; MIC90, 8 microg/ml), 2 Rhodotorula spp. (4.6% of isolates, MIC90, 1 microg/ml), 8 Trichosporon spp. (33.3% of isolates; MIC90, 64 microg/ml), and 1 C. lipolytica (50% of isolates). Interestingly, most C. albicans (67 out of 77 isolates) resistant to 5FC were serotype B isolates.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15538829

Source DB:  PubMed          Journal:  Rev Iberoam Micol        ISSN: 1130-1406            Impact factor:   1.044


  9 in total

1.  Novel 5-flucytosine-resistant clade of Candida dubliniensis from Saudi Arabia and Egypt identified by Cd25 fingerprinting.

Authors:  Asmaa Al Mosaid; Derek J Sullivan; Itzhack Polacheck; Faisal A Shaheen; Osama Soliman; Saleh Al Hedaithy; Sahar Al Thawad; Motaz Kabadaya; David C Coleman
Journal:  J Clin Microbiol       Date:  2005-08       Impact factor: 5.948

2.  Oral Candida isolates colonizing or infecting human immunodeficiency virus-infected and healthy persons in Mexico.

Authors:  Luis Octavio Sánchez-Vargas; Natalia Guadalupe Ortiz-López; María Villar; María Dolores Moragues; José Manuel Aguirre; Miguel Cashat-Cruz; Jose Luis Lopez-Ribot; Luis Alberto Gaitán-Cepeda; Guillermo Quindós
Journal:  J Clin Microbiol       Date:  2005-08       Impact factor: 5.948

Review 3.  Candida parapsilosis: from Genes to the Bedside.

Authors:  Renáta Tóth; Jozef Nosek; Héctor M Mora-Montes; Toni Gabaldon; Joseph M Bliss; Joshua D Nosanchuk; Siobhán A Turner; Geraldine Butler; Csaba Vágvölgyi; Attila Gácser
Journal:  Clin Microbiol Rev       Date:  2019-02-27       Impact factor: 26.132

4.  Evaluation of the new chromogenic medium Candida ID 2 for isolation and identification of Candida albicans and other medically important Candida species.

Authors:  Elena Eraso; María D Moragues; María Villar-Vidal; Ismail H Sahand; Nagore González-Gómez; José Pontón; Guillermo Quindós
Journal:  J Clin Microbiol       Date:  2006-09       Impact factor: 5.948

5.  Mutational analysis of flucytosine resistance in Candida glabrata.

Authors:  Thomas D Edlind; Santosh K Katiyar
Journal:  Antimicrob Agents Chemother       Date:  2010-09-07       Impact factor: 5.191

Review 6.  Case Report of Cryptococcus Albidus Peritonitis in a Peritoneal Dialysis Patient and a Review of the Literature.

Authors:  Loheetha Ragupathi; Maria Reyna
Journal:  Perit Dial Int       Date:  2014-03-01       Impact factor: 1.756

Review 7.  Candida parapsilosis, an emerging fungal pathogen.

Authors:  David Trofa; Attila Gácser; Joshua D Nosanchuk
Journal:  Clin Microbiol Rev       Date:  2008-10       Impact factor: 26.132

8.  Clonal population of flucytosine-resistant Candida tropicalis from blood cultures, Paris, France.

Authors:  Marie Desnos-Ollivier; Stéphane Bretagne; Claire Bernède; Vincent Robert; Dorothée Raoux; Elisabeth Chachaty; Elisabeth Forget; Claire Lacroix; Françoise Dromer
Journal:  Emerg Infect Dis       Date:  2008-04       Impact factor: 6.883

9.  Genetic diversity and antifungal susceptibility testing of Trichosporon asahii isolated of Intensive Care Units patients.

Authors:  Rosana Bellan de Oliveira Silva; Ana Marisa Fusco-Almeida; Marcelo Teruyuki Matsumoto; Lilian Cristiane Baeza; Tatiane Benaducci; Maria José Soares Mendes-Giannini
Journal:  Braz J Microbiol       Date:  2008-09-01       Impact factor: 2.476

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.